Clinical Trial Detail

NCT ID NCT03519178
Title A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Pfizer
Indications

ovary epithelial cancer

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

peritoneum cancer

fallopian tube cancer

Therapies

PF-06873600

Age Groups: adult

Additional content available in CKB BOOST